Researchers at Mass General Brigham found that by December 2023, over one-third of all new prescriptions for type 2 diabetes were for GLP-1 receptor agonists, such as semaglutide or tirzepatide. New research shows a major shift in how weight loss and type 2 diabetes are managed, with newer drugs like tirzepatide rapidly replacing older medications … Read more
Injectables for type 2 diabetes and weight loss could soon be a thing of the past. Eli Lilly announced Thursday the successful completion of a phase 3 trial of Orforglipron – the first small-molecule GLP-1 that is administered as a once-daily oral pill. The ACHIEVE-1 trial evaluated the efficacy of Orforglipron compared to placebo in … Read more
The experimental drug, orforglipron, led to weight loss of nearly 8 percent at the highest dose, besting Wall Street expectations and sending Lilly’s shares up.
Lilly’s Weight-Loss Pill Data Achieves “Best-Case Scenario”, Sending Rival Novo Shares Into Abyss Eli Lilly shares surged 16% in late afternoon trading—marking their largest intraday gain since August 2023—after the pharmaceutical giant announced earlier that its new weight-loss pill met efficacy goals in a late-stage trial, intensifying—if not turbocharging—its rivalry with Ozempic maker Novo Nordisk. … Read more
2025-04-17T13:01:58Z A sign for Eli Lilly & Co stands outside its corporate headquarters in Indianapolis A significant trial of a daily weight-loss pill has found that it helped people to shed the pounds and reduce their blood sugar levels, making it a contender to join the new wave of drugs that combat obesity and diabetes. … Read more
THURSDAY, April 17, 2025 — Both glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) are associated with a reduced risk for Alzheimer disease and related dementias (ADRDs) among people with…
What You Should Know: – Eli Lilly and Company announced positive topline Phase 3 results from ACHIEVE-1, a study evaluating the safety and efficacy of orforglipron compared to placebo in adults with type 2 diabetes whose blood sugar was inadequately controlled through diet and exercise alone. – Orforglipron stands out as the first oral small … Read more
Science, Volume 388, Issue 6744, Page 241-242, April 2025.
It’s little secret that America has a weight problem. For decades, Americans have embraced and abandoned countless weight-loss strategies, including fad diets, that have proven ineffective long term. Despite our best efforts, more people are at risk of health complications resulting from obesity, including type 2 diabetes and heart disease. Related: UnitedHealth stock tumbles after Medicare Advantage … Read more
